GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Cyclically Adjusted PB Ratio

NanoVibronix (NanoVibronix) Cyclically Adjusted PB Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NanoVibronix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NanoVibronix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Cyclically Adjusted PB Ratio Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NanoVibronix's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, NanoVibronix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Cyclically Adjusted PB Ratio falls into.



NanoVibronix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NanoVibronix's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, NanoVibronix's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.949/129.4194*129.4194
=1.949

Current CPI (Dec. 2023) = 129.4194.

NanoVibronix Quarterly Data

Book Value per Share CPI Adj_Book
201403 -28.588 99.695 -37.112
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -43.011 99.070 -56.187
201503 1.731 99.621 2.249
201506 11.258 100.684 14.471
201509 3.852 100.392 4.966
201512 -1.616 99.792 -2.096
201603 -4.635 100.470 -5.971
201606 -8.858 101.688 -11.274
201609 -12.192 101.861 -15.491
201612 -18.999 101.863 -24.139
201703 -21.308 102.862 -26.809
201706 -23.192 103.349 -29.042
201709 -32.596 104.136 -40.510
201712 18.456 104.011 22.965
201803 15.001 105.290 18.439
201806 11.208 106.317 13.643
201809 6.978 106.507 8.479
201812 2.425 105.998 2.961
201903 -2.311 107.251 -2.789
201906 9.329 108.070 11.172
201909 10.050 108.329 12.007
201912 6.394 108.420 7.632
202003 2.290 108.902 2.721
202006 -3.653 108.767 -4.347
202009 5.223 109.815 6.155
202012 2.252 109.897 2.652
202103 3.604 111.754 4.174
202106 3.453 114.631 3.898
202109 6.409 115.734 7.167
202112 4.510 117.630 4.962
202203 3.758 121.301 4.010
202206 2.953 125.017 3.057
202209 2.253 125.227 2.328
202212 1.970 125.222 2.036
202303 1.325 127.348 1.347
202306 0.701 128.729 0.705
202309 2.546 129.860 2.537
202312 1.949 129.419 1.949

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NanoVibronix  (NAS:NAOV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NanoVibronix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022